罗格列酮和匹格列酮间无明显差别。
No difference between rosiglitazone and pioglitazone was apparent.
目的：合成盐酸吡格列酮。
它的部分经费由吡格列酮的制造商武田制药提供。
It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
吡格列酮增加严重的心衰，虽然死亡率没有增加。
Serious heart failure is increased by pioglitazone, although without an associated increase in mortality.
目的：研究曲格列酮的肝细胞毒性及其可能的机制。
Objective: to explore hepatotoxicity of troglitazone on rat hepatocytes.
结论上述结果表明，曲格列酮可以引起混合型细胞死亡。
Conclusion Troglitazone induced mixed type of cell death in HeLa cells.
表2列举了吡格列酮及对照组共19项试验的临床结果。
TABLE 2 lists the clinical outcome measures in the pioglitazone and control groups of the 19 individual trials.
有关罗格列酮的一些负面新闻是否会对吡格列酮有影响？
Has some of the bad press and issues with rosiglitazone unfairly affected pioglitazone?
《国际糖尿病》：吡格列酮对血脂的作用是否优于罗格列酮？
International Diabetes: Does pioglitazone have more favorable effects on serum lipids than rosiglitazone?
当你观察吡格列酮复合的荟萃分析数据，它倾向于好的方面。
When you look at the composite meta-analysis data for pioglitazone, it falls on the good side.
巴格列酮的毒性已经经过一个综合性的非临床毒理研究程序鉴定。
The toxicity of balaglitazone was characterized in a comprehensive non-clinical toxicology programme.
目的建立检测中药降糖制剂中非法掺入的吡格列酮专属性方法。
OBJECTIVE to develop a specific method for the identification of pioglitazone illegally added into traditional Chinese medicine antidiabetic preparations.
从1999年开始，马来酸罗格列酮和盐酸匹格列酮被批准使用。
Beginning in 1999, rosiglitazone maleate and pioglitazone hydrochloride were approved for use.
结论吡格列酮、非诺贝特对大鼠能量代谢及体脂分布的影响不同。
Conclusion Pioglitazone and fenofibrate have different influences on energy homeostasis and body fat distribution in rats.
目的观察吡格列酮对2型糖尿病患者胰岛素敏感性和脂代谢的影响。
Objective Observe the effect of pioglitazone on insulin sensitivity and lipid metabolism in type 2 Diabetes Mellitus Patients.
这些早期的结果显示吡格列酮应用与膀胱癌风险之间没有总体的联系。
These early results showed no overall association between Actos exposure and risk of bladder cancer.
我个人的观点是吡格列酮应当在市场上保留，只用应用时多点儿谨慎。
My personal view is that pioglitazone should stay on the market and just be used a little more carefully.
结论：在不同的糖尿病人中，吡格列酮明显降低死亡，心肌梗塞，和中风。
CONCLUSIONS: Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes.
一半组员6个月期间每天服用45毫克吡格列酮，而剩下一半为安慰剂治疗。
About half of the group was given 45 milligrams of pioglitazone daily for six months, while the other half received a placebo.
吡格列酮联用磺脲类、胰岛素或者二甲双胍用于8项试验(8501个病人)。
Pioglitazone was tested in combination with a sulfonylurea, insulin, or metformin in 8 trials (8501 patients).
与安慰剂组的14%相比，服用吡格列酮组肝脏的胰岛素敏感型改善了48%。
Insulin sensitivity in the liver improved by 48 percent in the pioglitazone group, compared to 14 percent in the placebo group.
目的观察吡格列酮治疗糖尿病前期患者血管内皮细胞功能的变化及其可能的机制。
Objective To study whether pioglitazone therapy ameliorates endothelial dysfunction in pre-diabetic patients and the mechanism of it.
作者在文中总结称：根据我们的研究结果，联合阿维A和比格列酮可增强银屑病疗效。
"According to our study results, the addition of pioglitazone to acitretin therapy can enhance antipsoriatic efficacy, " the authors conclude.
结论吡格列酮可明显减少早期糖尿病肾病患者的UAER，并有显著降低血糖的作用。
Conclusion Pioglitazone can obviously decrease UAER of patients with early DN, and have the function of lowering the blood sugar.
目的观察胰岛素或胰岛素加吡格列酮治疗磺脲类继发失效2型糖尿病的疗效和安全性。
Objective It is to observe the curative effect and safety of insulin or insulin combined with pioglitazone on type 2 diabetes with sulfonylurea secondum refractoriness.
结论R2很可能是胰岛素增敏剂吡格列酮改善肝脏胰岛素敏感性的重要作用机制之一。
Conclusions The increased expression of R2 mRNA may play a important role in pioglitazone-induced insulin sensitivity amelioration.
这个时候，FDA的审核即将开始。该机构还没有得出结论说吡格列酮增加膀胱癌风险。
At this time, the FDA's review is ongoing. The agency has not concluded that Actos increases the risk of bladder cancer.
《国际糖尿病》：罗格列酮和吡格列酮对心血管的影响是否有所差别？二者有何相似性？
International Diabetes: Do rosiglitazone and pioglitazone have different or similar properties in respect to their cardiovascular profiles?
但是，这一发现可能低估了匹格列酮的益处，因为继发于初始事件的继发事件也被减少。
This finding, however, might be an underestimate of the benefit of pioglitazone, since events subsequent to the initial one are also reduced.
在使用匹格列酮的患者中，严重的心力衰竭增加，但是没有引起与之相关的死亡率的增加。
Serious heart failure is increased in patients on pioglitazone, although there is no associated increase in mortality.
应用推荐